Efficacy of SGLT2 inhibitors on bone mineral density in patients with type 2 diabetes

Efficacy of SGLT2 inhibitors on bone mineral density in patients with type 2 diabetes - Efficacy of SGLT2 inhibitors on bone mineral density in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016921

Enrollment

120

Registered

2015-03-26

Start date

2014-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Luseogliflozin Dapagliflozin Tofogliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients. Obtained written informed consent from the patients before participation.

Exclusion criteria

Exclusion criteria: Complicated severe nephropathy.

Design outcomes

Primary

Measure	Time frame
Bone mineral density compared to that of a young adult mean	—

Secondary

Measure	Time frame
Hemoglobin A1c level, body mass index, renal function parameters in blood and urine and serum lipid profiles	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Aichi Medical University Medical Clinic

info@tonyo.jp052-931-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026